What do systematic reviews say?

Topical aminocaproic acid vs placebo

Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).

• Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
  RR 0.48 [0.2, 1.1]
  2 studies · 131 participants
  Low

Systemic tranexamic acid vs control

Systemic tranexamic acid may leads to lower secondary hemorrhage at any time point compared with control (low certainty).

• Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.21, 0.53]
  7 studies · 754 participants
  Low

Systemic aminocaproic acid vs placebo

Systemic aminocaproic acid may leads to lower secondary hemorrhage at any time point compared with placebo (low certainty).

• Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
  RR 0.28 [0.13, 0.6]
  6 studies · 330 participants
  Low

Angiotensin‐converting enzyme inhibitors vs vitamin C

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin analogues vs biphasic insulin

It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.44, 1.56]
  2 studies · 500 participants
  Very low

Culturally and literacy adapted audio‐/visual education without personal feedback vs another culturally and literacy adapted audio‐/visual education without personal feedback

• Interventions for improving health literacy in migrants 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Very low

H2 receptor antagonists vs placebo

H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

• Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 1.07 [0.72, 1.57]
  2 studies · 189 participants
  Low

Monoamine modulators vs placebo

Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).

• Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 1.05 [0.56, 1.94]
  3 studies · 115 participants
  Low

Topiramate vs placebo or no treatment

Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).

• Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 1.09 [0.85, 1.41]
  2 studies · 132 participants
  Low

Metformin vs placebo or no treatment

It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).

• Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 1.02 [0.25, 4.13]
  4 studies · 137 participants
  Very low

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avoralstat vs placebo

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Double primary (canine and first molar) tooth extraction vs Single primary (canine) tooth extraction

The review found no eligible studies for this question.

• Interventions for promoting the eruption of palatally displaced permanent canine teeth, without the need for surgical… 2021 · Cochrane All outcomes
  The studies did not report adverse events.
  0 studies
  No studies found

Cisapride vs placebo

The review found no eligible studies for this question.

• Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical mydriatics vs intracameral mydriatics

Topical mydriatics showed no clear difference in AE: cystoid macular edema ‐ any time point during or after surgery compared with intracameral mydriatics (low certainty).

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.01, 7.83]
  1 study · 555 participants
  Low

Topical mydriatics vs depot delivery systems

The review found no eligible studies for this question.

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical mydriatics vs intracameral mydriatics

Topical mydriatics showed no clear difference in AE: posterior capsule rupture—any time point during or after surgery compared with intracameral mydriatics (low certainty).

• Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.01, 7.83]
  1 study · 555 participants
  Low

Bovine colostrum vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found